# Experimental Therapeutics Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $79,592

## Abstract

Experimental Therapeutics Program: Summary
The overarching mission of the Experimental Therapeutics (ET) Program is to discover and validate
therapeutic targets and subsequently identify, develop, and test novel therapeutic strategies and biomarkers.
The close collaboration between discovery scientists and clinicians allows a multifaceted assessment of
therapeutic strategies in iterative cycles from bench to bedside. Discoveries within the rich scientific
environment of the HDFCCC have resulted in the development of a large number of biotech start-ups, and the
movement of discoveries into the private sector for clinical implementation. Most often, this takes the form of
early biotech start-ups launched by UCSF faculty. Thus, this discovery cycle can also include `bench to
boardroom,' since the lengthy arc from initial discovery to clinical approval and adoption requires industrial
participation ranging from early biotech start-ups to pharmaceutical companies. Genomic and molecular
imaging target validation are a central clinical focus of the ET Program. Promising clinical translational
strategies are tested in the HDFCCC Early Phase Clinical Trials Unit. In addition to facilitating translation of
science from its members, the ET Program serves as a clinical translational hub for the entire HDFCCC, since
all clinical investigators in the ET Program participate in disease-specific Site Committees. These investigators
consequently serve as a two-way conduit of collaborative interactions between the Site Committees and the
ET Program. Research in the ET Program is conducted under two cross-cutting themes:
Theme 1: Targeting Signal Transduction in Cancer
Theme 2: Targeting Epigenetic Modulation, Cellular Homeostasis, and the Tumor Environment
ET Program: Key Metrics
Membership (13 departments, 2 schools) 43
Full 31
Associate 12
Cancer-relevant Funding (direct costs as of
$21,511,484
05/31/2017)
NCI $3,071,012 14%
Peer-reviewed $3,740,309 17%
Non-peer-reviewed $14,700,162 68%
Cancer-relevant Publications (1/2012-7/2017) 672
Inter-programmatic 262 39%
Intra-Programmatic 150 22%
High-Impact 189 28%
Accruals to Clinical Trials (2016) 237 63
Therapeutic 133 59
Other Interventional 0 2
Non-interventional 104 2

## Key facts

- **NIH application ID:** 9965773
- **Project number:** 5P30CA082103-21
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Pamela N. Munster
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $79,592
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9965773

## Citation

> US National Institutes of Health, RePORTER application 9965773, Experimental Therapeutics Program (5P30CA082103-21). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9965773. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*